51 related articles for article (PubMed ID: 11500516)
21. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
Hayashi N; Iwamoto T; Gonzalez-Angulo AM; Ferrer-Lozano J; Lluch A; Niikura N; Bartholomeusz C; Nakamura S; Hortobagyi GN; Ueno NT
Oncologist; 2011; 16(7):956-65. PubMed ID: 21712485
[TBL] [Abstract][Full Text] [Related]
22. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
[TBL] [Abstract][Full Text] [Related]
23. Calmodulin binds HER2 and modulates HER2 signaling.
White CD; Li Z; Sacks DB
Biochim Biophys Acta; 2011 May; 1813(5):1074-82. PubMed ID: 21185879
[TBL] [Abstract][Full Text] [Related]
24. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
25. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T; Wang Y; Zhao ZJ; Gu H
J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
[TBL] [Abstract][Full Text] [Related]
26. Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity.
Lucs AV; Muller WJ; Muthuswamy SK
Oncogene; 2010 Jan; 29(2):174-87. PubMed ID: 19826412
[TBL] [Abstract][Full Text] [Related]
27. p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin.
Kedinger V; Sansregret L; Harada R; Vadnais C; Cadieux C; Fathers K; Park M; Nepveu A
J Biol Chem; 2009 Oct; 284(40):27701-11. PubMed ID: 19635798
[TBL] [Abstract][Full Text] [Related]
28. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth.
Proietti CJ; Rosemblit C; Beguelin W; Rivas MA; Díaz Flaqué MC; Charreau EH; Schillaci R; Elizalde PV
Mol Cell Biol; 2009 Mar; 29(5):1249-65. PubMed ID: 19103753
[TBL] [Abstract][Full Text] [Related]
29. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.
Portera CC; Walshe JM; Rosing DR; Denduluri N; Berman AW; Vatas U; Velarde M; Chow CK; Steinberg SM; Nguyen D; Yang SX; Swain SM
Clin Cancer Res; 2008 May; 14(9):2710-6. PubMed ID: 18451236
[TBL] [Abstract][Full Text] [Related]
30. Prediction of phosphotyrosine signaling networks using a scoring matrix-assisted ligand identification approach.
Li L; Wu C; Huang H; Zhang K; Gan J; Li SS
Nucleic Acids Res; 2008 Jun; 36(10):3263-73. PubMed ID: 18424801
[TBL] [Abstract][Full Text] [Related]
31. Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion.
Northey JJ; Chmielecki J; Ngan E; Russo C; Annis MG; Muller WJ; Siegel PM
Mol Cell Biol; 2008 May; 28(10):3162-76. PubMed ID: 18332126
[TBL] [Abstract][Full Text] [Related]
32. ShcA signalling is essential for tumour progression in mouse models of human breast cancer.
Ursini-Siegel J; Hardy WR; Zuo D; Lam SH; Sanguin-Gendreau V; Cardiff RD; Pawson T; Muller WJ
EMBO J; 2008 Mar; 27(6):910-20. PubMed ID: 18273058
[TBL] [Abstract][Full Text] [Related]
33. Ets2 is required for trophoblast stem cell self-renewal.
Wen F; Tynan JA; Cecena G; Williams R; Múnera J; Mavrothalassitis G; Oshima RG
Dev Biol; 2007 Dec; 312(1):284-99. PubMed ID: 17977525
[TBL] [Abstract][Full Text] [Related]
34. Emerging therapies in gastrointestinal cancers.
Nautiyal J; Rishi AK; Majumdar AP
World J Gastroenterol; 2006 Dec; 12(46):7440-50. PubMed ID: 17167831
[TBL] [Abstract][Full Text] [Related]
35. Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays.
Smith MJ; Hardy WR; Murphy JM; Jones N; Pawson T
Mol Cell Biol; 2006 Nov; 26(22):8461-74. PubMed ID: 16982700
[TBL] [Abstract][Full Text] [Related]
36. Roles for neuregulins in human cancer.
Stove C; Bracke M
Clin Exp Metastasis; 2004; 21(8):665-84. PubMed ID: 16035612
[TBL] [Abstract][Full Text] [Related]
37. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Podsypanina K; Li Y; Varmus HE
BMC Med; 2004 Jun; 2():24. PubMed ID: 15198801
[TBL] [Abstract][Full Text] [Related]
38. Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins.
Howard PL; Chia MC; Del Rizzo S; Liu FF; Pawson T
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11267-72. PubMed ID: 13679576
[TBL] [Abstract][Full Text] [Related]
39. Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins.
Dankort D; Jeyabalan N; Jones N; Dumont DJ; Muller WJ
J Biol Chem; 2001 Oct; 276(42):38921-8. PubMed ID: 11500516
[TBL] [Abstract][Full Text] [Related]
40. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.
Dankort D; Maslikowski B; Warner N; Kanno N; Kim H; Wang Z; Moran MF; Oshima RG; Cardiff RD; Muller WJ
Mol Cell Biol; 2001 Mar; 21(5):1540-51. PubMed ID: 11238891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
